Active Ingredient History

  • Now
Perifosine is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT. It was being developed by Keryx Biopharmaceuticals who had licensed it from Æterna Zentaris Inc.   Wikipedia

  • Mol. Mass: 461.67
  • ALogP: 6.99
  • ChEMBL Molecule:
More Chemistry
d 21266 | d-21266 | krx-0401 | octadecyl-(1,1-dimethyl-4-piperidylio)phosphate | perifosine


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue